1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Tafasitamab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Combination With Immunomodulatory Agents (Such As Lenalidomide)
  • 1.3.3 Combination With Chemotherapy Or Other Targeted Therapies
• 1.4 Market Analysis by Specification
  • 1.4.1 Overview: Global Tafasitamab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
  • 1.4.2 200 mg / vial
  • 1.4.3 800 mg/vial
• 1.5 Market Analysis by Production Technology
  • 1.5.1 Overview: Global Tafasitamab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
  • 1.5.2 Innovator
  • 1.5.3 Generic
• 1.6 Market Analysis by Dosage Form
  • 1.6.1 Overview: Global Tafasitamab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
  • 1.6.2 Lyophilized Powder for Injection
  • 1.6.3 Injection Solution
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Tafasitamab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
  • 1.7.3 B-Cell Non-Hodgkin Lymphoma (B-NHL)
  • 1.7.4 CD19-Positive Hematologic Malignancies
  • 1.7.5 Precision Hematologic Cancer Therapy
  • 1.7.6 Others
• 1.8 Global Tafasitamab Market Size & Forecast
  • 1.8.1 Global Tafasitamab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Tafasitamab Sales Quantity (2021-2032)
  • 1.8.3 Global Tafasitamab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 MorphoSys AG
  • 2.1.1 MorphoSys AG Details
  • 2.1.2 MorphoSys AG Major Business
  • 2.1.3 MorphoSys AG Tafasitamab Product and Services
  • 2.1.4 MorphoSys AG Tafasitamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 MorphoSys AG Recent Developments/Updates
• 2.2 Incyte Corporation
  • 2.2.1 Incyte Corporation Details
  • 2.2.2 Incyte Corporation Major Business
  • 2.2.3 Incyte Corporation Tafasitamab Product and Services
  • 2.2.4 Incyte Corporation Tafasitamab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Incyte Corporation Recent Developments/Updates

3 Competitive Environment: Tafasitamab by Manufacturer

• 3.1 Global Tafasitamab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Tafasitamab Revenue by Manufacturer (2021-2026)
• 3.3 Global Tafasitamab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Tafasitamab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Tafasitamab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Tafasitamab Manufacturer Market Share in 2025
• 3.5 Tafasitamab Market: Overall Company Footprint Analysis
  • 3.5.1 Tafasitamab Market: Region Footprint
  • 3.5.2 Tafasitamab Market: Company Product Type Footprint
  • 3.5.3 Tafasitamab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Tafasitamab Market Size by Region
  • 4.1.1 Global Tafasitamab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Tafasitamab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Tafasitamab Average Price by Region (2021-2032)
• 4.2 North America Tafasitamab Consumption Value (2021-2032)
• 4.3 Europe Tafasitamab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Tafasitamab Consumption Value (2021-2032)
• 4.5 South America Tafasitamab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Tafasitamab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Tafasitamab Sales Quantity by Type (2021-2032)
• 5.2 Global Tafasitamab Consumption Value by Type (2021-2032)
• 5.3 Global Tafasitamab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Tafasitamab Sales Quantity by Application (2021-2032)
• 6.2 Global Tafasitamab Consumption Value by Application (2021-2032)
• 6.3 Global Tafasitamab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Tafasitamab Sales Quantity by Type (2021-2032)
• 7.2 North America Tafasitamab Sales Quantity by Application (2021-2032)
• 7.3 North America Tafasitamab Market Size by Country
  • 7.3.1 North America Tafasitamab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Tafasitamab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Tafasitamab Sales Quantity by Type (2021-2032)
• 8.2 Europe Tafasitamab Sales Quantity by Application (2021-2032)
• 8.3 Europe Tafasitamab Market Size by Country
  • 8.3.1 Europe Tafasitamab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Tafasitamab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Tafasitamab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Tafasitamab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Tafasitamab Market Size by Region
  • 9.3.1 Asia-Pacific Tafasitamab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Tafasitamab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Tafasitamab Sales Quantity by Type (2021-2032)
• 10.2 South America Tafasitamab Sales Quantity by Application (2021-2032)
• 10.3 South America Tafasitamab Market Size by Country
  • 10.3.1 South America Tafasitamab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Tafasitamab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Tafasitamab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Tafasitamab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Tafasitamab Market Size by Country
  • 11.3.1 Middle East & Africa Tafasitamab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Tafasitamab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Tafasitamab Market Drivers
• 12.2 Tafasitamab Market Restraints
• 12.3 Tafasitamab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Tafasitamab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Tafasitamab
• 13.3 Tafasitamab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Tafasitamab Typical Distributors
• 14.3 Tafasitamab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Tafasitamab market size was valued at US$ 350 million in 2025 and is forecast to a readjusted size of US$ 812 million by 2032 with a CAGR of 11.5% during review period.
Tafasitamab is a humanized CD19-targeted monoclonal antibody primarily used in the treatment of B-cell malignancies. It specifically binds to the CD19 antigen expressed on the surface of B cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and other immune-mediated mechanisms, thereby promoting the elimination of malignant B cells. Tafasitamab is typically used in combination with immunomodulatory agents such as lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It has significant clinical value in the field of hematologic cancer targeted therapy.In 2025, global production of tafasitamab reached approximately 150,000units.
Tafasitamab, as a CD19-targeted monoclonal antibody, occupies an important niche in the treatment market for B-cell non-Hodgkin lymphoma, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). With the steady increase in the global incidence of hematologic malignancies and the growing demand for novel immuno-targeted therapies, the CD19-targeted drug market is gradually expanding. Tafasitamab has demonstrated clinical efficacy in combination with lenalidomide, enabling it to gain guideline recommendations and improve its clinical penetration. From a competitive landscape perspective, this field is not only dominated by long-established CD20 monoclonal antibodies such as rituximab, but also faces competitive pressure from emerging CD19/CD79b-targeted therapies. Looking ahead, with the accumulation of real-world evidence, expansion of indications, and commercialization in emerging markets, the market size of tafasitamab is expected to maintain steady growth, continuing to play an important role in the precision treatment landscape of B-cell lymphoma.
This report is a detailed and comprehensive analysis for global Tafasitamab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tafasitamab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tafasitamab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tafasitamab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tafasitamab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tafasitamab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tafasitamab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include MorphoSys AG, Incyte Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tafasitamab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Combination With Immunomodulatory Agents (Such As Lenalidomide)
Combination With Chemotherapy Or Other Targeted Therapies
Market segment by Specification
200 mg / vial
800 mg/vial
Market segment by Production Technology
Innovator
Generic
Market segment by Dosage Form
Lyophilized Powder for Injection
Injection Solution
Market segment by Application
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
B-Cell Non-Hodgkin Lymphoma (B-NHL)
CD19-Positive Hematologic Malignancies
Precision Hematologic Cancer Therapy
Others
Major players covered
MorphoSys AG
Incyte Corporation
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tafasitamab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tafasitamab, with price, sales quantity, revenue, and global market share of Tafasitamab from 2021 to 2026.
Chapter 3, the Tafasitamab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tafasitamab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tafasitamab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tafasitamab.
Chapter 14 and 15, to describe Tafasitamab sales channel, distributors, customers, research findings and conclusion.